A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

Key facts

Sponsor

Ruijin Hospital

Intervention

LCAR-HL30 cells(biological)

Enrollment

32 enrolled

Eligibility

18-75 years · All sexes

Timeline

2024 – 2028

Study locations (1)

• Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Collaborators

Nanjing Legend Biotech Co.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Anaplastic large cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06561048
  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
  Corvus Pharmaceuticals, Inc.
• RECRUITINGPHASE1, PHASE2NCT06137144
  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
  AstraZeneca
• ACTIVE NOT RECRUITINGPHASE1NCT04526834
  Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
  Tessa Therapeutics
• ACTIVE NOT RECRUITINGPHASE3NCT04881838
  CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL
  Children's Cancer Group, China
• ACTIVE NOT RECRUITINGPHASE2NCT02978625
  Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
  National Cancer Institute (NCI)
• RECRUITINGNCT04220970
  Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
  The Lymphoma Academic Research Organisation

See all trials for Anaplastic large cell lymphoma →